

PAIN

1. Drug discovery targeting GPCR and ion channel is still difficult with small molecules and antibodies.
2. Conventional peptide drugs has limitations in pharmacokinetics and administration.

【Background Issue】

GPCRs and ion channels have become increasingly important drug targets, especially in unmet fields such as cancer and autoimmune diseases. However, more than 75% of GPCRs and ion channels remain unexplored due to technical difficulties in drug discovery, as represented by the followings:

【Small molecule compounds】

- Designing molecules with the desired activity and

selectivity

【Antibodies】

- Discovery of antibodies against GPCRs and ion channels
- Low tissue permeability

【Linear and cyclic peptides】

- Archive desirable pharmacokinetics due to stability, solubility, and molecular size issues


Our solution

Taylor-made molecular design using disulfide-rich peptides with molecular properties not found in small molecules, antibodies, or cyclic peptides

Next-generation Drug Generation Engine

High-speed DRP drug discovery for “Hard” drug targets

1. DRP Space™



DRP Library Construction

Large drug source


2. PERISS™



DRP Screening

High speed & low-cost drug selection

3. Anchor™



DRP Evaluation

4. Super Secrete™



DRP Production

Low-cost drug production